Clinical trial
Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem
NCT00319982 · Brigham and Women's Hospital, Other · Completed
Key facts
| NCT number | NCT00319982 |
|---|---|
| Title | Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem |
| Official title | Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem |
| Lead sponsor | Brigham and Women's Hospital, Other |
| Collaborators | National Heart, Lung, and Blood Institute (NHLBI) NIH Boston Children's Hospital |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Hypertrophic Cardiomyopathy |
| Intervention type | Drug |
| Interventions | Diltiazem, Placebo |
| Enrollment | 39 |
| Start date | Jan 1, 2006 |
| Primary completion | Dec 1, 2012 |
| Completion | Dec 1, 2013 |
| First posted | Apr 27, 2006 |
| Last update posted | Apr 7, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: